Sanofi pasteur is the vaccine division of the sanofi-aventis Group. Our industrial organization In terms of industrial organization, our strategy is defined on a global basis and then adapted and implemented locally. The production of our vaccines is managed globally and ensured through multi-site production, which makes it possible to diversify our sources of supply. This organization is better for customers because it reduces the risk of supply issues. Fruitful synergies between the sites Sanofi pasteur has four major production sites: in France in Marcy-l'Étoile (near Lyon) and Val-de-Reuil (near Rouen), in the US in Swiftwater, Pennsylvania and in Canada in Toronto. Over the past few years, the company has also developed new production sites in China, Thailand, and Argentina. Each of these production facilities has its own specific characteristics, fostering synergies. The diversification of resources for the supply of vaccines is an advantage for customers since it means there is a reliable supply of vaccine to meet demand. It also represents greater efficiency on the market. Mastering the cold chain In order to be effective, vaccines must be maintained at the right temperature from production through administration. Specific storage and transport conditions must be carefully observed. The oral polio vaccine, for example, must be kept at - 20° C. Sanofi pasteur's expertise in this field is unrivaled and represents a unique competitive advantage internationally, the result of the company's experience in more than 150 countries. We have developed a comprehensive cold chain management system, which enables our packages to maintain the correct temperature under any delivery conditions. Investing to increase capacity To meet steadily growing demand, sanofi pasteur has made substantial investments in recent years. From 1997 to 2001, the company invested 50% more than during the five previous years. In 2002, we launched a program to invest over 255 million euros in our production capacity in France and the United States, where we also began construction work on important new research buildings. In recent years, the sums devoted to capital investments have reached nearly 10% of our company's revenues. Our objective is to optimize production capacities to meet demand, which is expected to double by 2010. We want to be the first to be able to meet customer needs globally with a reliable supply of quality vaccines.